Caris and Xencor expand collaboration for XmAb antibody drug candidates

Repurposed drug has promising efficacy in shrinking NSCLC tumors

An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer with KRAS mutations, a clinical trial led by UT Southwestern Harold C. Simmons Comprehensive Cancer Center researchers showed.

December 13, 2024

Vol.50 No.46

Drugs & Targets

Dewpoint Therapeutics and ConcertAI form drug development partnership

Dewpoint Therapeutics and ConcertAI announced the first phase of their Translational Oncology partnership, aligned around Dewpoint’s latest drug candidate, DPTX3186.

December 13, 2024

Vol.50 No.46

Drugs & Targets

FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients

FDA has approved MI Cancer Seek for use as a companion diagnostic to identify patients with cancer who may benefit from treatment with targeted therapies.

November 08, 2024

Vol.50 No.42

In Brief

ECOG-ACRIN, Caris collaborate on interrogating TAILORx breast cancer trial

ECOG-ACRIN Cancer Research Group and Caris Life Sciences announced a multi-year research collaboration wherein Caris is pairing its genomic, transcriptomic, and proteomic profiling, advanced artificial intelligence and machine learning algorithms with ECOG-ACRIN’s research capabilities.

October 25, 2024

Vol.50 No.40

Clinical Trials & Tribulations

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.

July 26, 2024

Vol.50 No.30

By Jacquelyn Cobb and Paul Goldberg

Caris and Xencor expand collaboration for XmAb antibody drug candidates

YOU MAY BE INTERESTED IN

Repurposed drug has promising efficacy in shrinking NSCLC tumors

Dewpoint Therapeutics and ConcertAI form drug development partnership

FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients

ECOG-ACRIN, Caris collaborate on interrogating TAILORx breast cancer trial

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Renew today!

Subscriber content

Never miss an issue!

Login

Caris and Xencor expand collaboration for XmAb antibody drug candidates

YOU MAY BE INTERESTED IN

Repurposed drug has promising efficacy in shrinking NSCLC tumors

Dewpoint Therapeutics and ConcertAI form drug development partnership

FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients

ECOG-ACRIN, Caris collaborate on interrogating TAILORx breast cancer trial

Of adaptive and factorial designsA biostatistician’s interpretation of last week’s ODAC

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Never miss an issue!

Login

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC